Vor Biopharma Inc. (NASDAQ:VOR) Receives $42.25 Average PT from Brokerages

Vor Biopharma Inc. (NASDAQ:VOR) has earned a consensus rating of “Moderate Buy” from the eleven brokerages that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, six have given a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $42.25.

Several research firms have recently issued reports on VOR. Jefferies Financial Group raised shares of Vor Biopharma to a “strong-buy” rating in a research note on Thursday, April 30th. Wall Street Zen downgraded Vor Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Weiss Ratings upgraded Vor Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, June 30th. HC Wainwright reaffirmed a “buy” rating and set a $31.00 target price on shares of Vor Biopharma in a research report on Monday, May 18th. Finally, Wedbush lifted their target price on Vor Biopharma from $15.00 to $18.00 and gave the stock a “neutral” rating in a report on Thursday, May 14th.

Vor Biopharma Stock Performance

NASDAQ:VOR opened at $20.05 on Wednesday. The stock’s 50-day moving average is $16.02 and its 200-day moving average is $15.10. Vor Biopharma has a 1-year low of $6.50 and a 1-year high of $53.00.

Vor Biopharma (NASDAQ:VOR) last issued its quarterly earnings data on Monday, March 30th. The company reported $307.61 earnings per share (EPS) for the quarter. On average, research analysts forecast that Vor Biopharma will post -2.51 earnings per share for the current year.

Institutional Trading of Vor Biopharma

Several institutional investors have recently added to or reduced their stakes in VOR. UBS Group AG raised its holdings in Vor Biopharma by 284.8% during the 4th quarter. UBS Group AG now owns 292,118 shares of the company’s stock worth $3,821,000 after purchasing an additional 216,209 shares during the last quarter. Frazier Life Sciences Management L.P. bought a new stake in shares of Vor Biopharma in the 4th quarter valued at $33,275,000. NEXTBio Capital Management LP acquired a new stake in shares of Vor Biopharma during the fourth quarter worth $13,080,000. Simplify Asset Management Inc. acquired a new stake in shares of Vor Biopharma during the first quarter worth $955,000. Finally, Findell Capital Management LLC bought a new position in Vor Biopharma during the fourth quarter worth $3,021,000. 97.29% of the stock is currently owned by institutional investors.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).